Cargando…

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis

Detalles Bibliográficos
Autor principal:	Jeena, Prakash Mohan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	South African Medical Association 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432923/ https://www.ncbi.nlm.nih.gov/pubmed/34541494 http://dx.doi.org/10.7196/SARJ.2018.v24i1.202

Ejemplares similares

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

An update on respiratory syncytial virus
por: Piralla, Antonio, et al.
Publicado: (2023)

Respiratory Syncytial Virus Infection in High-Risk Infants
por: Resch, Bernhard
Publicado: (2011)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Porcine epidemic diarrhea virus infection: Etiology, epidemiology, pathogenesis and immunoprophylaxis
por: Jung, Kwonil, et al.
Publicado: (2015)

Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step
por: Billard, Marie-Noëlle, et al.
Publicado: (2021)

Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
por: Menasalvas Ruiz, Ana Isabel
Publicado: (2023)

Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
por: Menasalvas Ruiz, Ana Isabel
Publicado: (2023)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

The Changing Landscape of Respiratory Syncytial Virus Infections
por: Bem, Reinout A., et al.
Publicado: (2023)

The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease
por: Thwaites, Ryan S., et al.
Publicado: (2019)

Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study
por: Terletskaia-Ladwig, Elena, et al.
Publicado: (2005)

IgY antibodies for the immunoprophylaxis and therapy of respiratory infections
por: Abbas, Aymn Talat, et al.
Publicado: (2018)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali
por: Buchwald, Andrea G, et al.
Publicado: (2020)

Fail-Fast in Respiratory Syncytial Virus Vaccine Development
por: Besteman, Sjanna B., et al.
Publicado: (2019)

Epidemiology, Molecular Epidemiology and Evolution of Bovine Respiratory Syncytial Virus
por: Sarmiento-Silva, Rosa Elena, et al.
Publicado: (2012)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Molecular epidemiology of respiratory syncytial virus transmission in childcare
por: Chu, Helen Y., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_98c9b2ie7d133m6pga9bvrs8u0